Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSHR | P16473 | 1/20 | 0.75 |
| ▸ | MAOB | P27338 | 3/20 | 0.50 |
| ▸ | CYP2A6 | P11509 | 2/20 | 0.50 |
| ▸ | MAOA | P21397 | 2/20 | 0.50 |
| ▸ | HTR2C | P28335 | 1/20 | 0.48 |
| ▸ | DRD4 | P21917 | 2/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.44 |
| ▸ | PLAU | P00749 | 1/20 | 0.44 |
| ▸ | NOS3 | P29474 | 1/20 | 0.43 |
| ▸ | PNMT | P11086 | 1/20 | 0.42 |
| ▸ | CD44 | P16070 | 1/20 | 0.42 |
| ▸ | IDO1 | P14902 | 2/20 | 0.41 |
| ▸ | BCHE | P06276 | 1/20 | 0.40 |
| ▸ | DRD2 | P14416 | 1/20 | 0.40 |
| ▸ | DRD1 | P21728 | 1/20 | 0.40 |
| ▸ | DRD5 | P21918 | 1/20 | 0.40 |
| ▸ | DRD3 | P35462 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrazine SCHEMBL1878369 | 0.93 | TSHR (0.87) | TSHRMAOBCYP2A6MAOAHTR2C | |
| SCHEMBL3057782 | 0.93 | TSHR (0.86) | TSHRMAOBCYP2A6MAOAHTR2C | |
| SCHEMBL9662 | 0.93 | — | — | |
| SCHEMBL29354295 | 0.93 | — | — | |
| SCHEMBL451157 | 0.93 | TSHR (0.86) | TSHRMAOBCYP2A6MAOAHTR2C | |
| Methylamine SCHEMBL27846987 | 0.90 | TSHR (0.71) | TSHRMAOBCYP2A6MAOAHTR2C | |
| Methylamine SCHEMBL2462109 | 0.90 | TSHR (0.71) | TSHRMAOBCYP2A6MAOAHTR2C | |
| Ammonia Solution, Strong SCHEMBL6332955 | 0.90 | TSHR (0.80) | TSHRMAOBCYP2A6MAOAHTR2C | |
| Methane SCHEMBL19946467 | 0.90 | TSHR (0.80) | TSHRMAOBCYP2A6MAOAHTR2C | |
| SCHEMBL6277308 | 0.90 | TSHR (0.80) | TSHRMAOBCYP2A6MAOAHTR2C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2706999-B1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2019-08-28 | — | — | EP | disclosed |
| EP-2498609-B1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | CELGENE INT II SARL (CH) | 2018-04-18 | — | — | EP | disclosed |
| CN-107661500-A | The inhibitor of VAP 1 is used for the purposes for treating fibrotic conditions | 生物结治疗公司 | 2018-02-06 | — | — | CN | disclosed |
| WO-2012158550-A9 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | RECEPTOS, INC. (US) | 2017-10-26 | — | — | WO | disclosed |
| US-9481659-B2 | Selective heterocyclic sphingosine 1 phosphate receptor modulators | CELGENE INTERNATIONAL II SÀRL (CH) | 2016-11-01 | — | — | US | disclosed |
| CN-102753022-B | Selective heterocyclic sphingosine 1-phosphate receptor modulators | RECEPTOS, INC. (US) | 2016-04-20 | — | — | CN | disclosed |
| CN-105130922-A | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | RECEPTOS INC | 2015-12-09 | — | — | CN | disclosed |
| US-20150299179-A1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | RECEPTOS, INC. (US) | 2015-10-22 | — | — | US | disclosed |
| US-20150252037-A1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | RECEPTOS LLC | 2015-09-10 | — | — | US | disclosed |
| EP-2706999-A2 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | Receptos, Inc. (US) | 2014-03-19 | — | — | EP | disclosed |
| US-20140039183-A1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | RECEPTOS LLC | 2014-02-06 | — | — | US | disclosed |
| CN-1914224-B | HCV NS-3 serine protease inhibitors | MEDIVIR AB | 2014-01-29 | — | — | CN | disclosed |
| US-8507538-B2 | Selective heterocyclic sphingosine 1 phosphate receptor modulators | RECEPTOS, INC. (US) | 2013-08-13 | — | — | US | disclosed |
| WO-2012158550-A2 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | RECEPTOS, INC. (US) | 2012-11-22 | — | — | WO | disclosed |
| CN-102753022-A | Selective heterocyclic sphingosine 1-phosphate receptor modulators | RECEPTOS INC | 2012-10-24 | — | — | CN | disclosed |
| CN-102740886-A | Use of VAP-1 inhibitors for the treatment of fibrotic diseases | BIOTIE THERAPIES CORP | 2012-10-17 | — | — | CN | disclosed |
| US-20110183953-A1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | RECEPTOS LLC | 2011-07-28 | — | — | US | disclosed |
| CN-1914224-A | HCV NS-3 serine protease inhibitors | MEDIVIR AB (SE) | 2007-02-14 | — | — | CN | disclosed |
| CN-1118476-C | Antiviral protease inhibitors | MEDIVIR AB (SE) | 2003-08-20 | — | — | CN | disclosed |
| CN-1258301-A | Antiviral protease inhibitors | MEDIVIR AB (SE) | 2000-06-28 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140039183-A1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | S1PR1, S1PR3, S1PR2 | TSHR 449/4885MAOB 2472/4885CYP2A6 1268/4885 |
| US-20150252037-A1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | S1PR1, S1PR3, S1PR2 | TSHR 449/4885MAOB 2472/4885CYP2A6 1268/4885 |
| US-20150299179-A1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | S1PR1, S1PR3, S1PR2 | TSHR 453/4885MAOB 2488/4885CYP2A6 1278/4885 |
| US-20110183953-A1 | SELECTIVE HETEROCYCLIC SPHINGOSINE 1 PHOSPHATE RECEPTOR MODULATORS | S1PR1, S1PR3, S1PR2 | TSHR 453/4885MAOB 2488/4885CYP2A6 1278/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.